

DAY 1: Wednesday, 21 June 2017		
0800 – 0830	Registration	
0830 – 0845	Opening of Meeting	Martin Friede (WHO) David Kaslow (PATH)
Coordination of WHO and IVB vaccine product development activities		
0845 – 0915	A year in review	Birgitte Giersing (WHO)
0915 - 0945	Update from other IVB committees: IPAC and IVIRAC	Anna-Lea Kahn (WHO) Raymond Hutubessy (WHO)
0945 – 1000	Update from WHO SAGE committee	Alejandro Cravioto (SAGE)
1000 -1015	Update on Zika vaccine activities	Joachim Hombach (WHO)
1015 - 1045	COFFEE	
Novel antigen delivery platforms and approaches		
1045 – 1145	Advances in nucleic acid delivery vaccine platforms	David Kaslow (PATH) Barney Graham (NIAID)
1145 - 1215	Maternal immunization (MI) delivery platform	Ruth Karron (JHU)
1215 – 1245	WHO R&D Observatory, Update on TPPs related to emerging pathogens	Vasee Moorthy (WHO)
1245 – 1345	LUNCH	
1345 – 1415	Group B Streptococcus	Shabir Mahdi (NICD) Andy Pollard (University of Oxford) by phone
1415 – 1445	Respiratory Syncytial Virus	Fernando Polack (Vanderbilt) Filip Dubovsky (Medimmune)
1445 – 1545	Influenza (novel vaccine approaches)	Joachim Hombach (WHO) Fatimah Dawood (CDC) – by phone Armen Donabedian/ Ruben Donis (BARDA)- by phone
1545 – 1615	COFFEE	
1615 - 1645	Development and access to monoclonal antibodies for passive immunization	Erin Sparrow (WHO)
The role of vaccines with respect to antimicrobial resistance (AMR) and examples of selected pathogens		
1645 – 1700	Value of Vaccines in the Avoidance of AMR	Charles Clift (Chatham House)
1700 - 1745	Staphylococcus aureus	Annaliesa Anderson (Pfizer) Filip Dubovsky (Medimmune)

DAY2: Thursday, 22 June 2017		
The role of vaccines with respect to AMR and examples of selected pathogens (Cont)		
0830 – 0900	Group A Streptococcus	Andrew Steer (Murdoch Children’s Research Institute)
0900 – 0930	Gonorrhoea	Sami Gottlieb (WHO) Ann Jerse (Uniformed Services University of the Health Sciences)
Vaccine development efforts related to HIV and TB		
0930 – 1000	Herpes Simplex Virus	Carolyn Deal (NIAID) Sami Gottlieb (WHO)
1000 – 1030	Human Immunodeficiency Virus	Kundai Chinyenze (IAVI)
1030 – 1100	COFFEE	
1100 – 1130	Tuberculosis	Lewis Schrager (Independent)
Vaccine delivery and total systems effectiveness		
1130 – 1145	The concept of total systems effectiveness	Patrick Lydon (WHO)
1145 – 1215	Overview of emerging delivery technologies	Darin Zehrung (PATH)
1215 – 1315	LUNCH	
Enteric vaccine development and other vaccine R&D activities		
1315 – 1400	Cytomegalovirus (CMV)	Stanley Plotkin (by phone)
1400 – 1450	Enterotoxigenic E. coli (ETEC) and Shigella	Lou Bourgeois (JHU/PATH)
1450 – 1500	Cholera	Adwoa Bentsi-Enchill (WHO)
1500 – 1520	Child Health and Mortality Prevention Surveillance (CHAMPS)	Shabir Mahdi (NICD)
1520 – 1540	BMGF Medical Research Institute	Penny Heaton (BMGF)
1540 – 1600	COFFEE BREAK	
Assessment of the vaccine value proposition		
1600 – 1630	GAVI Vaccine Investment Strategy (VIS)	Judith Kallenberg (GAVI)
1630 – 1700	Rabies	Bernadette Abela-Ridder (WHO)
1700 – 1715	IVR’s role in vaccine development	Martin Friede (WHO)
1715	Meeting close	